On Tuesday, December 23, 2025, Rep. Dan Meuser of Pennsylvania praised President Donald Trump’s expanding agreements with major pharmaceutical companies to lower prescription drug prices, calling the effort “a fantastic development” that he said could save Americans “tens of billions of dollars.”
The remarks followed the White House announcement that nine additional drugmakers had agreed to participate in the administration’s “most-favored-nation” pricing initiative, bringing the total number of companies participating to 14. Under this approach, the administration has sought to tie certain U.S. drug prices to the lowest prices paid by other wealthy countries.
In an interview, Meuser stated: “I’ve been an advocate, as has the president, for a long time, that our Centers for Medicare and Medicaid Services should be able to negotiate directly with pharmaceutical companies.” The administration described the new commitments as expanding price reductions beyond existing government programs and reaching consumers who pay cash or face high out-of-pocket costs.
The agreements include commitments to lower prices for some medicines and offer discounted purchases through a new direct-to-consumer platform the White House said would launch in January. Meuser emphasized that under the framework, manufacturers “will need to go to your pharmacist,” with prices expected to be “lower” as part of a negotiated, most-favored-nation threshold. He also highlighted the TrumpRx initiative as a key component of the administration’s plan, stating: “It’s America First. It’s access, it’s lower pricing.”
The White House has framed the effort as building on President Donald Trump’s May 2025 executive order directing agencies to pursue most-favored-nation pricing and other steps intended to align certain U.S. prices more closely with those paid abroad. The Department of Health and Human Services and the Centers for Medicare and Medicaid Services have stated they are moving to implement this order.
This policy push occurs alongside a separate federal effort under the Inflation Reduction Act, which has already negotiated “maximum fair prices” for an initial set of 10 Part D drugs, with those prices scheduled to take effect on January 1, 2026. Consumer advocates and health policy groups have reported that these negotiated prices are expected to lower out-of-pocket costs for many Medicare beneficiaries in early 2026.
However, the impact of the Trump administration’s new agreements might be difficult to predict quickly. While the administration touted significant potential savings, some experts noted that the magnitude would depend on how the commitments are implemented and how broadly the discounts apply across markets. Meuser emphasized speed and scale, saying Americans would soon “feel the impact” as the initiative moved from announcements to purchasing and pharmacy channels in early 2026.
